BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 15534051)

  • 21. Shortened PET data acquisition protocol for the quantification of 18F-FDG kinetics.
    Strauss LG; Dimitrakopoulou-Strauss A; Haberkorn U
    J Nucl Med; 2003 Dec; 44(12):1933-9. PubMed ID: 14660719
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Breast Cancer Blood Flow and Metabolism on Dual-Acquisition
    Humbert O; Lasserre M; Bertaut A; Fumoleau P; Coutant C; Brunotte F; Cochet A
    J Nucl Med; 2018 Jul; 59(7):1035-1041. PubMed ID: 29439010
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Untreated primary lung and breast cancers: correlation between F-18 FDG kinetic rate constants and findings of in vitro studies.
    Torizuka T; Zasadny KR; Recker B; Wahl RL
    Radiology; 1998 Jun; 207(3):767-74. PubMed ID: 9609902
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prospective comparison of 18F-FDG PET with conventional imaging modalities (MRI, CT, and 67Ga scintigraphy) in assessment of combined intraarterial chemotherapy and radiotherapy for head and neck carcinoma.
    Kitagawa Y; Nishizawa S; Sano K; Ogasawara T; Nakamura M; Sadato N; Yoshida M; Yonekura Y
    J Nucl Med; 2003 Feb; 44(2):198-206. PubMed ID: 12571209
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quantitative assessment of heterogeneity in tumor metabolism using FDG-PET.
    Vriens D; Disselhorst JA; Oyen WJ; de Geus-Oei LF; Visser EP
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):e725-31. PubMed ID: 22330998
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chemotherapy response monitoring of colorectal liver metastases by dynamic Gd-DTPA-enhanced MRI perfusion parameters and 18F-FDG PET metabolic rate.
    Vriens D; van Laarhoven HW; van Asten JJ; Krabbe PF; Visser EP; Heerschap A; Punt CJ; de Geus-Oei LF; Oyen WJ
    J Nucl Med; 2009 Nov; 50(11):1777-84. PubMed ID: 19837750
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SUV varies with time after injection in (18)F-FDG PET of breast cancer: characterization and method to adjust for time differences.
    Beaulieu S; Kinahan P; Tseng J; Dunnwald LK; Schubert EK; Pham P; Lewellen B; Mankoff DA
    J Nucl Med; 2003 Jul; 44(7):1044-50. PubMed ID: 12843218
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chemotherapy response evaluation with 18F-FDG PET in patients with non-small cell lung cancer.
    de Geus-Oei LF; van der Heijden HF; Visser EP; Hermsen R; van Hoorn BA; Timmer-Bonte JN; Willemsen AT; Pruim J; Corstens FH; Krabbe PF; Oyen WJ
    J Nucl Med; 2007 Oct; 48(10):1592-8. PubMed ID: 17873138
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acute changes in regional cerebral (18)F-FDG kinetics in patients with traumatic brain injury.
    Hattori N; Huang SC; Wu HM; Liao W; Glenn TC; Vespa PM; Phelps ME; Hovda DA; Bergsneider M
    J Nucl Med; 2004 May; 45(5):775-83. PubMed ID: 15136626
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis.
    Avril N; Menzel M; Dose J; Schelling M; Weber W; Jänicke F; Nathrath W; Schwaiger M
    J Nucl Med; 2001 Jan; 42(1):9-16. PubMed ID: 11197987
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Simplified kinetic analysis of tumor 18F-FDG uptake: a dynamic approach.
    Sundaram SK; Freedman NM; Carrasquillo JA; Carson JM; Whatley M; Libutti SK; Sellers D; Bacharach SL
    J Nucl Med; 2004 Aug; 45(8):1328-33. PubMed ID: 15299057
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Decreased 18F-FDG uptake 1 day after initiation of chemotherapy for malignant lymphomas.
    Yamane T; Daimaru O; Ito S; Yoshiya K; Nagata T; Ito S; Uchida H
    J Nucl Med; 2004 Nov; 45(11):1838-42. PubMed ID: 15534052
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quantification of liver glucose metabolism by positron emission tomography: validation study in pigs.
    Iozzo P; Jarvisalo MJ; Kiss J; Borra R; Naum GA; Viljanen A; Viljanen T; Gastaldelli A; Buzzigoli E; Guiducci L; Barsotti E; Savunen T; Knuuti J; Haaparanta-Solin M; Ferrannini E; Nuutila P
    Gastroenterology; 2007 Feb; 132(2):531-42. PubMed ID: 17258736
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of anesthetic agents and fasting duration on 18F-FDG biodistribution and insulin levels in tumor-bearing mice.
    Lee KH; Ko BH; Paik JY; Jung KH; Choe YS; Choi Y; Kim BT
    J Nucl Med; 2005 Sep; 46(9):1531-6. PubMed ID: 16157537
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor 18F-FDG incorporation is enhanced by attenuation of P53 function in breast cancer cells in vitro.
    Smith TA; Sharma RI; Thompson AM; Paulin FE
    J Nucl Med; 2006 Sep; 47(9):1525-30. PubMed ID: 16954562
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO.
    Gebhart G; Gámez C; Holmes E; Robles J; Garcia C; Cortés M; de Azambuja E; Fauria K; Van Dooren V; Aktan G; Coccia-Portugal MA; Kim SB; Vuylsteke P; Cure H; Eidtmann H; Baselga J; Piccart M; Flamen P; Di Cosimo S
    J Nucl Med; 2013 Nov; 54(11):1862-8. PubMed ID: 24092940
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of tumor volumes derived from glucose metabolic rate maps and SUV maps in dynamic 18F-FDG PET.
    Visser EP; Philippens ME; Kienhorst L; Kaanders JH; Corstens FH; de Geus-Oei LF; Oyen WJ
    J Nucl Med; 2008 Jun; 49(6):892-8. PubMed ID: 18483085
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Does the pretreatment tumor sampling location correspond with metabolic activity on 18F-FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy?
    Koolen BB; Elshof LE; Loo CE; Wesseling J; Vrancken Peeters MJ; Vogel WV; Rutgers EJ; Valdés Olmos RA
    Eur J Radiol; 2013 Dec; 82(12):2353-8. PubMed ID: 23998705
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Repeat 18F-FDG PET for monitoring neoadjuvant chemotherapy in patients with stage III non-small cell lung cancer.
    Eschmann SM; Friedel G; Paulsen F; Reimold M; Hehr T; Budach W; Dittmann H; Langen HJ; Bares R
    Lung Cancer; 2007 Feb; 55(2):165-71. PubMed ID: 17129635
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic aspects of 18F-FDG PET kinetics in patients with metastatic colorectal carcinoma receiving FOLFOX chemotherapy.
    Dimitrakopoulou-Strauss A; Strauss LG; Burger C; Rühl A; Irngartinger G; Stremmel W; Rudi J
    J Nucl Med; 2004 Sep; 45(9):1480-7. PubMed ID: 15347714
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.